Biocept and University of California, Irvine to Study Blood-based Liquid Biopsy Testing in Cancer Patients
The National Comprehensive Cancer Network (NCCN) guidelines recommend
testing of key biomarkers in patients with lung cancer such as EGFR, ALK
and ROS1. Test results from these biomarkers are used to qualify
patients for targeted therapies that have demonstrated improved
survival, such as Roche's Tarceva® for patients with
EGFR+ lung cancer and Pfizer's Xalkori® for patients
with ALK+ lung cancer. Current testing methods rely on tumor tissue from
invasive biopsy and/or surgical tissue removal. Both procedures can
entail significant patient risk and healthcare expense. Further, tissue
biopsies can fail to contain adequate tumor tissue for biomarker
analyses. In these instances, it is believed that a blood-based liquid
biopsy, such as those offered by
"We expect that our collaboration with the University of
"We are very excited to work closely with the University of
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which they
are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of these
words or other variations on these words or comparable terminology. To
the extent that statements in this release are not strictly historical,
including without limitation statements as to our ability to validate
the use of liquid biopsies for targeted therapies, the ability to
identify indicators of resistance to therapy, our liquid biopsy
technology providing accurate biomarker information, the results of our
collaboration with the University of
View source version on businesswire.com: http://www.businesswire.com/news/home/20150811005120/en/
Investor Contact:
LHA
310-691-7100
jcain@lhai.com
Source:
News Provided by Acquire Media